Capital markets intelligence for management teams and boards operating in healthcare and AI/technology.
The MedTech financing market has restructured around a smaller number of larger, more selective investors — and the bar for what a fundable company looks like has moved accordingly. In this briefing, we examine where capital is actually flowing across device sub-segments, how underwriting criteria have shifted at seed through growth stages, and the three structural changes management teams should build into their next raise strategy.
Read article →Where institutional healthcare capital is deploying, how valuations have moved by sub-sector, and what that means for companies planning a raise in the next twelve months.
The diligence frameworks sophisticated technology investors now apply to AI companies — and what separates durable businesses from those built on temporary advantages.
A practical framework for evaluating non-dilutive capital against stage, revenue profile, and milestone timing — and the structures to avoid.
The narrative, data, and materials package institutional healthcare investors expect before a first meeting — from regulatory pathway to unit economics.
Venture debt, revenue-based financing, royalty structures, and government-linked capital — how each instrument works and where it fits.
Why single-buyer negotiations systematically underprice companies — and how process design creates the competitive tension that discovers true strategic value.
The assumptions that collapse under diligence, the scenario architecture investors expect, and how to build a model that survives the second meeting.
A case study in running parallel processes — and how optionality between instruments strengthened the company's negotiating position in both.
How the regulatory pathway for AI/ML-based devices is shifting — and what that means for financing timelines, valuation, and investor diligence.